DOCSLIB.ORG

Neurokinin Receptor NK Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neurokinin Receptor NK Receptor Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Inhibitors & Modulators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Bioactivity: Aprepitant (MK-0869) is a selective and high-affinity Bioactivity: Befetupitant is a high-affinity, nonpeptide, competitive neurokinin 1 receptor antagonist with a Kd of 86 pM. tachykinin 1 receptor ( NK1R) antagonist. Purity: 99.93% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 mg, 5 mg, 10 mg, 20 mg 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg Fezolinetant Fosaprepitant (ESN-364) Cat. No.: HY-19632 (L-758298) Cat. No.: HY-14407 Bioactivity: Fezolinetant is an antagonist of the neurokinin 3 receptor Bioactivity: Fosaprepitant (L-758298) is a neurokinin-1 receptor antagonist (NK3R), used for the treatment of menopausal hot flushes. for the prevention of chemotherapy-induced nausea and vomiting. Purity: 98.29% Purity: >98% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 5 mg, 10 mg, 50 mg 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Fosaprepitant dimeglumine GR 159897 (MK-0517; L785298) Cat. No.: HY-14407A Cat. No.: HY-107691 Bioactivity: Fosaprepitant dimeglumine(MK-0517) is a neurokinin-1 receptor Bioactivity: GR 159897 is a highly potent, selective, competitive, antagonist for the prevention of chemotherapy-induced nausea brain-penetrated non-peptide antagonist at tachykinin NK2 and vomiting. IC50 Value: Target: NK1 receptor in vitro: receptors, inhibits binding of [ 3H]GR100679 to hNK -CHO Fosaprepitant (also known as MK-0517 and L-758,298) is a 2 water-soluble phosphoryl prodrug for aprepitant, which, when… cells and rat colon membranes with pKis of 9.51 and … Purity: 99.0% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg Size: Hemokinin 1 mouse Ibodutant Cat. No.: HY-P1030 (MEN 15596) Cat. No.: HY-14770 Bioactivity: Hemokinin 1 (mouse) is a selective agonist of neurokinin-1 Bioactivity: Ibodutant (MEN 15596) is a potent and selective tachykinin NK2 receptor, with Ki of 0.175 nM and 560 nM for human NK1 receptor antagonist with a pKi of 10.1. receptor and human NK2 receptor, respectively. Purity: 98.41% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 250 mg, 500 mg Kassinin Maropitant Cat. No.: HY-P0250 Cat. No.: HY-10053 Bioactivity: Kassinin is a peptide derived from the Kassina frog. It Bioactivity: Maropitant is a neurokinin (NK1) receptor antagonist. IC50 belongs to tachykinin family of neuropeptides. It is secreted value: Target: NK1 receptor Maropitant is the first NK1 as a defense response, and is involved in neuropeptide receptor antagonist developed to treat and prevent emesis in signalling. dogs. Treatment with 1 mg/kg Maropitant citrate, significantly reduced the size of ulcerative dermatitis (UD) lesions in… Purity: >98% Purity: 99.00% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Men 10376 Men 10376 TFA (Neurokinin-2 receptor antagonist) Cat. No.: HY-P1276 (Neurokinin-2 receptor antagonist (TFA)) Cat. No.: HY-P1276A Bioactivity: Men 10376 is a selective tachykinin NK-2 receptor antagonist, Bioactivity: Men 10376 TFA is a selective tachykinin NK-2 receptor with a Ki of 4.4 μM for rat small intestine NK-2 receptor. antagonist, with a Ki of 4.4 μM for rat small intestine NK-2 receptor [1]. Purity: >98% Purity: 99.76% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 1 mg, 5 mg, 10 mg MEN11467 Monohydroxy Netupitant D6 Cat. No.: HY-U00207 Cat. No.: HY-G0012S Bioactivity: MEN11467 is a selective and orally- effective peptidomimetic Bioactivity: Monohydroxy Netupitant D6 is the deuterium labeled Monohydroxy tachykinin NK1 receptor antagonist. Netupitant, which is a metabolite of Netupitant. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg Size: 1 mg, 5 mg, 10 mg Netupitant Netupitant D6 (CID 6451149) Cat. No.: HY-16346 (CID-6451149 D6) Cat. No.: HY-16346S Bioactivity: Netupitant (CID-6451149) is a highly potent and selective, Bioactivity: Netupitant D6 is the deuterium labeled orally active neurokinin-1 receptor antagonist with Ki of 0.95 Netupitant(CID-6451149), which is a highly potent and nM. IC50 value: 0.95 nM (Ki) [1] Target: NK1 receptor in selective, orally active neurokinin-1 receptor antagonist. vitro: Netupitant also dose-dependently inhibited the SP response as expected from an NK1 receptor antagonist.… Purity: 99.78% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 mg, 5 mg, 10 mg 5 mg, 10 mg, 50 mg, 100 mg Netupitant metabolite Monohydroxy Netupitant Neurokinin A (Monohydroxy Netupitant) Cat. No.: HY-G0012 (α-Neurokinin; Neuromedin L; Substance K) Cat. No.: HY-P0197 Bioactivity: Monohydroxy Netupitant is the metabolite of Netupitant, which Bioactivity: Neurokinin A acts via neurokinin 2 ( NK-2) receptor. is a highly selective NK1 receptor antagonist. Purity: >98% Purity: 98.92% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 1 mg, 5 mg, 10 mg, 25 mg Neurokinin A(4-10) Neurokinin A(4-10) TFA Cat. No.: HY-P0236 Cat. No.: HY-P0236A Bioactivity: Neurokinin A (4-10) is a tachykinin NK2 receptor agonist. Bioactivity: Neurokinin A (4-10) TFA is a tachykinin NK2 receptor agonist [1]. Purity: >98% Purity: 98.48% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg, 10 mg, 25 mg www.MedChemExpress.com 3 Neurokinin antagonist 1 Neurokinin B Cat. No.: HY-U00320 Cat. No.: HY-P0242 Bioactivity: Neurokinin antagonist 1 is a Neurokinin antagonist Bioactivity: Neurokinin B belongs to the tachykinin family of peptides. extracted from patent WO1998045262A1. Neurokinin B binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological effect [1]. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg Size: 1 mg, 5 mg, 10 mg, 25 mg Neurokinin B TFA NK-1 Antagonist 1 Cat. No.: HY-P0242A Cat. No.: HY-106659 Bioactivity: Neurokinin B TFA belongs to the tachykinin family of peptides. Bioactivity: NK-1 Antagonist 1 is an antagonist of NK-1 receptor, used in Neurokinin B binds a family of GPCRs-including neurokinin the research of NK-1 related diseases and conditions such as receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological cough, overactive bladder, alcohol dependency and depression. effect [1]. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in Water, Size: 250 mg, 500 mg 1 mg, 5 mg, 10 mg, 25 mg NKP608 Pavinetant Cat. No.: HY-18006 (MLE-4901; AZD2624; AZD4901) Cat. No.: HY-14432 Bioactivity: NKP608 is a non-peptidic derivative of 4-aminopiperidine which Bioactivity: Pavinetant (MLE-4901) is a neurokinin-3 receptor ( NK3R) acts as a selective, specific and potent antagonist at the antagonist. neurokinin-1 (NK-1) receptor both in vitro(IC50=2.6 nM) and in vivo. Purity: 99.34% Purity: 99.74% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Physalaemin Rolapitant Cat. No.: HY-P0255 (SCH619734) Cat. No.: HY-14751 Bioactivity: Physalaemin, a non-mammalian tachykinin, binds selectively to Bioactivity: Rolapitant (SCH619734) is a potent, selective and orally neurokinin-1 ( NK1) receptor with high affinity. active neurokinin NK1 receptor antagonist with a Ki of 0.66 nM. Purity: >98% Purity: 98.01% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg, 10 mg, 25 mg Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Saredutant SB-222200 (SR 48968; SR 48968C) Cat. No.: HY-106910 Cat. No.: HY-15722 Bioactivity: Saredutant is a selective NK2 receptor antagonist. Bioactivity: SB 222200 is a selective, reversible and competitive antagonist of human NK-3 receptor(Ki=4.4 nM) that effectively crosses the blood-brain barrier. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 250 mg, 500 mg Size: 10mM x 1mL in DMSO, 10 mg, 50 mg 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Scyliorhinin II Senktide Cat.
Load more

Recommended publications
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • CP.PMN.158 Netupitant and Palonosetron (Akynzeo)
    Clinical Policy: Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) Reference Number: CP.PMN.158 Effective Date: 09.01.06 Last Review Date: 02.21 Coding Implications Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Netupitant/palonosetron (Akynzeo®) and fosnetupitant/palonosetron are fixed combination products of netupitant, a substance P/neurokinin 1 (NK1) receptor antagonist, and palonosetron hydrochloride, a serotonin (5-HT3) receptor antagonist. FDA Approved Indication(s) Akynzeo capsules are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Akynzeo for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Akynzeo is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Prevention of Nausea and Vomiting Associated with Cancer Chemotherapy (must meet all): 1. Prescribed for the prevention of chemotherapy-induced nausea/vomiting; 2. Age ≥ 18 years; 3. If request is for Akynzeo capsules, member is scheduled to receive moderately to highly emetogenic cancer chemotherapy (see Appendix D); 4. If request is for Akynzeo for injection, member is scheduled to receive highly emetogenic cancer chemotherapy (see Appendix D); 5.
    [Show full text]
  • Fosaprepitant Dimeglumine (Emend® for Injection) Prior Authorization Drug Coverage Policy
    1 Fosaprepitant dimeglumine (Emend® for injection) Prior Authorization Drug Coverage Policy Effective Date: 9/1/2020 Revision Date: n/a Review Date: 3/13/20 Lines of Business: Commercial Policy type: Prior Authorization This Drug Coverage Policy provides parameters for the coverage of fosaprepitant dimeglumine. Consideration of medically necessary indications are based upon U.S. Food and Drug Administration (FDA) indications, recommended uses within the Centers of Medicare & Medicaid Services (CMS) five recognized compendia, including the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium (Category 1 or 2A recommendations), and peer-reviewed scientific literature eligible for coverage according to the CMS, Medicare Benefit Policy Manual, Chapter 15, section 50.4.5 titled, “Off-Label Use of Anti-Cancer Drugs and Biologics.” This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine. Drug Description 1 Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin- induced emesis.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Minilap: a MIGS Approach to the Benign Large Adnexal Mass Surgical Technique Video
    MDEDGE.COM/OBGYN | VOL 31, NO 4 | APRIL 2019 Society of Gynecologic Surgeons Annual Meeting Highlights Issue Peripartum depression: New counseling guidelines Robert L. Barbieri, MD Update on prenatal exome sequencing AAnnenne H.H. Mardy,Mardy, MD;MD; MaryMary E.E. Norton,Norton, MDMD A member of the Network Minilap: A MIGS approach to the benign large adnexal mass Surgical technique video Beyond ERAS Sean C. Dowdy, MD HT and Alzheimer disease: An association? Andrew M. Kaunitz, MD Vaginal anatomy for the gyn surgeon p. SS4 FoFollowllow us on FFacebookacebook aandnd Twitter C1 0419.indd 1 4/2/19 11:59 AM TAKE A NEXT STEP IN MODERATE TO SEVERE ENDOMETRIOSIS PAIN1 Clinical study design: Two robust, similar, multicenter, Dysmenorrhea double-blind, prospective, placebo-controlled phase 3 (150 mg or 200 mg) trials of 6-month treatment at 2 doses as compared with placebo in premenopausal women (18 to 49 years of age) Non-menstrual with surgically diagnosed endometriosis and moderate or Pelvic Pain (NMPP) severe endometriosis-associated pain (N=1686).1,2 (150 mg or 200 mg) • Co-primary efficacy endpoints (independently evaluated): proportion of responders for dysmenorrhea at month 3 1 Dyspareunia* and proportion of responders for NMPP at month 3 (200 mg only) *Statistical significance for dyspareunia was not achieved with the 150 mg QD dose of ORILISSA. INDICATION Change in Menstrual Bleeding Pattern and Reduced Ability to ORILISSA® (elagolix) is indicated for the management of Recognize Pregnancy moderate to severe pain associated with endometriosis. • Women who take ORILISSA may experience a reduction in the IMPORTANT SAFETY INFORMATION amount, intensity, or duration of menstrual bleeding, which may reduce the ability to recognize the occurrence of pregnancy CONTRAINDICATIONS in a timely manner.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • A Randomized, Double-Blind, Placebo-Controlled Study
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Mo%on Sifnos: A randomized, double-blind, placebo-controlled study demonstra%ng the effec%veness of tradipitant in the treatment of mo%on sickness Vasilios M. Polymeropoulos*1, Mark É. Czeisler1#a, Mary M. Gibson1¶, Aus%n A. Anderson1¶, Jane Miglo1#b, Jingyuan Wang1, Changfu Xiao1, Christos M. Polymeropoulos1, Gunther Birznieks1, Mihael H. Polymeropoulos1 1 Vanda Pharmaceu%cals, Washington, District of Columbia, United States of America #a The Ins%tute for Breathing and Sleeping, Aus%n Health, Heidelberg, Victoria, Australia #b College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, United States of America *Corresponding author Email: [email protected] (VMP) ¶These authors contributed equally to this work. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 2 Abstract Background Novel therapies are needed for the treatment of mo%on sickness given the inadequate relief, and bothersome and dangerous adverse effects of currently approved therapies.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • NEPA, a Fixed Oral Combination of Netupitant and Palonosetron
    Support Care Cancer DOI 10.1007/s00520-016-3502-x ORIGINAL ARTICLE NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron Matti Aapro1 & Meinolf Karthaus2 & Lee Schwartzberg3 & Igor Bondarenko4 & Tomasz Sarosiek 5 & Cristina Oprean6 & Servando Cardona-Huerta7 & Vincent Hansen 8 & Giorgia Rossi9 & Giada Rizzi9 & Maria Elisa Borroni9 & Hope Rugo10 Received: 14 May 2016 /Accepted: 25 September 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract with oral PALO in a single chemotherapy cycle; maintenance Purpose Antiemetic guidelines recommend co-administration of efficacy/safety over continuing cycles is the objective of this of targeted prophylactic medications inhibiting molecular path- study. ways involved in emesis. NEPA is a fixed oral combination of a Methods This study is a multinational, double-blind study new NK1 receptor antagonist (RA), netupitant (NETU 300 mg), comparing a single oral dose of NEPA vs oral PALO in and palonosetron (PALO 0.50 mg), a pharmacologically dis- chemotherapy-naïve patients receiving anthracycline/ tinct 5-HT3 RA. NEPA showed superior prevention of cyclophosphamide-based chemotherapy along with dexa- chemotherapy-induced nausea and vomiting (CINV) compared methasone12mg(NEPA)or20mg(PALO)onday1. The primary efficacy endpoint was delayed (25–120 h) A prior publication reported the cycle 1 findings of this study [Aapro complete response (CR: no emesis, no rescue medication) et al., Annals of Oncology 2014 NCT01339260]. This paper focuses on in cycle 1. Sustained efficacy was evaluated during the the findings in the multiple-cycle extension, data which was an oral pre- multicycle extension by calculating the proportion of pa- sentation at both the ASCO and MASCC Annual Meetings in 2014.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Compositions for Treating Centrally Mediated
    (19) TZZ Z_T (11) EP 2 722 045 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4178 (2006.01) A61K 31/473 (2006.01) 06.07.2016 Bulletin 2016/27 A61K 31/496 (2006.01) A61K 31/573 (2006.01) A61K 45/06 (2006.01) A61K 9/00 (2006.01) (2006.01) (2006.01) (21) Application number: 14151683.1 A61K 9/20 A61K 9/48 A61P 1/08 (2006.01) (22) Date of filing: 18.11.2010 (54) Compositions for treating centrally mediated nausea and vomiting Zusammensetzungen zur Behandlung von zentral vermitteltem Unwohlsein und Erbrechen Compositions pour traiter les nausées et vomissements à médiation centrale (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB WO-A1-2008/049552 WO-A2-2007/096763 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR • REDDY G KESAVA ET AL: "Novel neurokinin-1 antagonists as antiemetics for the treatment of (30) Priority: 18.11.2009 US 262470 P chemotherapy-induced emesis.", SUPPORTIVE 14.09.2010 US 382709 P CANCER THERAPY 1 APR 2006 LNKD- PUBMED:18632487, vol. 3, no. 3, 1 April 2006 (43) Date of publication of application: (2006-04-01), pages140-142, XP002626039, ISSN: 23.04.2014 Bulletin 2014/17 1543-2912 • DIEMUNSCH P ET AL: "Neurokinin-1 receptor (62) Document number(s) of the earlier application(s) in antagonists in the prevention of postoperative accordance with Art.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]